Literature DB >> 22940035

Prevalence and clinical relevance of Th17 cells in patients with gastric cancer.

Yoshinori Yamada1, Hiroaki Saito, Masahide Ikeguchi.   

Abstract

BACKGROUND: Th17 cells have recently been identified as a distinct T helper (Th) lineage in a cancer animal model and in human cancers. Their specific role in tumor immunity is unclear. We, therefore, sought to evaluate the role of Th17 cells in gastric cancer.
METHODS: The prevalence of Th1, Th2, Treg, and Th17 cells in both peripheral blood mononuclear cells (PBMC) and gastric tissue was evaluated by multicolor flow cytometry. The concentration of interleukin (IL)-17 in sera was quantitated by enzyme-linked immunosorbent assay.
RESULTS: We observed a clear difference in the prevalence of Th17 cells in PBMC (0.34 ± 0.24%) versus gastric cancer tissues (19.4 ± 12.1) (P = 0.0002). Subset-specific phenotypic analysis of CD4+ T cells in both PBMC and gastric cancer tissue showed that Th1 and Treg cells predominate in PBMC, whereas Th17 cells are the most abundant CD4+ T cell subset in cancerous tissue. The concentrations of IL-17, a hallmark of Th17, in gastric cancer patients and normal controls were 0.6 ± 0.67 and 0.16 ± 0.19 pg/mL (P = 0.0032). Five-year survival rates of patients with high IL-17 and low IL-17 concentration were 47.1% and 83.9% (P = 0.0075). Multivariate analysis indicated that IL-17 concentration was an independent prognostic indicator, as well as lymph node metastasis.
CONCLUSIONS: There was a significant skewing toward a Th17 phenotype in gastric cancer tissue. IL-17 seems to play an important role in the progression of gastric cancer.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22940035     DOI: 10.1016/j.jss.2012.07.055

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  29 in total

1.  Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients.

Authors:  Audrey Hennequin; Valentin Derangère; Romain Boidot; Lionel Apetoh; Julie Vincent; David Orry; Jean Fraisse; Sylvain Causeret; François Martin; Laurent Arnould; Françoise Beltjens; François Ghiringhelli; Sylvain Ladoire
Journal:  Oncoimmunology       Date:  2015-06-03       Impact factor: 8.110

2.  Th17 cell expansion in gastric cancer may contribute to cancer development and metastasis.

Authors:  Zhaoliang Su; Yingkun Sun; Haitao Zhu; Yueqin Liu; Xin Lin; Huiling Shen; Jianguo Chen; Wenlin Xu; Huaxi Xu
Journal:  Immunol Res       Date:  2014-01       Impact factor: 2.829

Review 3.  The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review.

Authors:  Simone Punt; Jessica M Langenhoff; H Putter; Gert Jan Fleuren; Arko Gorter; Ekaterina S Jordanova
Journal:  Oncoimmunology       Date:  2015-03-06       Impact factor: 8.110

4.  Prognostic significance of interleukin-17 in solid tumors: a meta-analysis.

Authors:  Yunhui Zeng; Qiongwen Zhang; Hong Wang; Minxun Lu; Hongyu Kong; Yingyi Zhang; Huashan Shi
Journal:  Int J Clin Exp Med       Date:  2015-07-15

5.  Clinical relevance of the number of interleukin-17-producing CD 8+ T cells in patients with gastric cancer.

Authors:  Hiroaki Saito; Yoshinori Yamada; Seigo Takaya; Tomohiro Osaki; Masahide Ikeguchi
Journal:  Surg Today       Date:  2015-04-14       Impact factor: 2.549

6.  Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis.

Authors:  Kepeng Wang; Min Kyoung Kim; Giuseppe Di Caro; Jerry Wong; Shabnam Shalapour; Jun Wan; Wei Zhang; Zhenyu Zhong; Elsa Sanchez-Lopez; Li-Wha Wu; Koji Taniguchi; Ying Feng; Eric Fearon; Sergei I Grivennikov; Michael Karin
Journal:  Immunity       Date:  2014-11-25       Impact factor: 31.745

7.  Local and systemic Th17 immune response associated with advanced stage colon cancer.

Authors:  Stephen P Sharp; Dorina Avram; Steven C Stain; Edward C Lee
Journal:  J Surg Res       Date:  2016-09-28       Impact factor: 2.192

8.  Th17 cytokines in non-melanoma skin cancer.

Authors:  Florencia McAllister; Jay K Kolls
Journal:  Eur J Immunol       Date:  2015-03       Impact factor: 5.532

Review 9.  A review of the application of inflammatory biomarkers in epidemiologic cancer research.

Authors:  Darren R Brenner; Dominique Scherer; Kenneth Muir; Joellen Schildkraut; Paolo Boffetta; Margaret R Spitz; Loic Le Marchand; Andrew T Chan; Ellen L Goode; Cornelia M Ulrich; Rayjean J Hung
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-06-24       Impact factor: 4.254

10.  Th17 cell-derived IL-17A promoted tumor progression via STAT3/NF-κB/Notch1 signaling in non-small cell lung cancer.

Authors:  Ruirui Wang; Li Yang; Chaoqi Zhang; Ruijie Wang; Zhen Zhang; Qianyi He; Xinfeng Chen; Bin Zhang; Zhihai Qin; Liping Wang; Yi Zhang
Journal:  Oncoimmunology       Date:  2018-08-23       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.